Burning Rock Biotech Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Burning Rock Biotech's earnings have been declining at an average annual rate of -14.6%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 9.5% per year.
Anahtar bilgiler
-14.6%
Kazanç büyüme oranı
14.7%
EPS büyüme oranı
Biotechs Sektör Büyümesi | 17.0% |
Gelir büyüme oranı | 9.5% |
Özkaynak getirisi | -83.6% |
Net Marj | -111.2% |
Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Little Excitement Around Burning Rock Biotech Limited's (NASDAQ:BNR) Revenues
Jun 21Will Burning Rock Biotech (NASDAQ:BNR) Spend Its Cash Wisely?
Mar 25There's No Escaping Burning Rock Biotech Limited's (NASDAQ:BNR) Muted Revenues
Feb 01Burning Rock Biotech Limited (NASDAQ:BNR) Shares Could Be 24% Below Their Intrinsic Value Estimate
Jul 12Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Deliver On Growth Plans?
Apr 28We Think Burning Rock Biotech (NASDAQ:BNR) Needs To Drive Business Growth Carefully
Dec 23Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Invest In Growth?
Sep 20Burning Rock Biotech GAAP EPS of -$0.37 misses by $0.01, revenue of $19.5M misses by $2.94M
Aug 31Burning Rock Localizes As Investors Grow Impatient
Jun 06We're Hopeful That Burning Rock Biotech (NASDAQ:BNR) Will Use Its Cash Wisely
Mar 24Following Rough Year, Is Burning Rock Set To Turn The Corner?
Nov 17Is Burning Rock Biotech (NASDAQ:BNR) Using Debt In A Risky Way?
Aug 27A Look At The Intrinsic Value Of Burning Rock Biotech Limited (NASDAQ:BNR)
Jul 23Is Burning Rock Biotech (NASDAQ:BNR) Using Debt Sensibly?
May 13Burning Rock Biotech Expands Test Portfolio In Bid For Growth
Dec 30Burning Rock inks license pact with Oncocyte Corporation
Dec 15Burning Rock Biotech prices upsized offering of 2.243M ADSs at $25.75/ADS
Dec 04Burning Rock Biotech EPS misses by $0.08, beats on revenue
Nov 20Gelir ve Gider Dağılımı
Burning Rock Biotech nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 510 | -567 | 640 | 288 |
31 Mar 24 | 521 | -590 | 638 | 319 |
31 Dec 23 | 537 | -654 | 686 | 347 |
30 Sep 23 | 559 | -708 | 735 | 372 |
30 Jun 23 | 586 | -764 | 788 | 397 |
31 Mar 23 | 570 | -895 | 900 | 397 |
31 Dec 22 | 563 | -971 | 939 | 422 |
30 Sep 22 | 568 | -1,006 | 965 | 434 |
30 Jun 22 | 540 | -945 | 925 | 394 |
31 Mar 22 | 537 | -887 | 853 | 410 |
31 Dec 21 | 508 | -797 | 793 | 368 |
30 Sep 21 | 492 | -702 | 720 | 339 |
30 Jun 21 | 490 | -659 | 674 | 338 |
31 Mar 21 | 469 | -564 | 570 | 301 |
31 Dec 20 | 430 | -472 | 462 | 264 |
30 Sep 20 | 387 | -450 | 390 | 233 |
30 Jun 20 | 367 | -389 | 316 | 202 |
31 Mar 20 | 345 | -347 | 291 | 166 |
31 Dec 19 | 382 | -334 | 285 | 157 |
30 Sep 19 | 358 | -268 | 248 | 137 |
31 Dec 18 | 209 | -232 | 191 | 105 |
31 Dec 17 | 111 | -185 | 144 | 49 |
Kaliteli Kazançlar: BNR is currently unprofitable.
Büyüyen Kar Marjı: BNR is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: BNR is unprofitable, and losses have increased over the past 5 years at a rate of 14.6% per year.
Büyüme Hızlandırma: Unable to compare BNR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: BNR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Özkaynak Getirisi
Yüksek ROE: BNR has a negative Return on Equity (-83.62%), as it is currently unprofitable.